

TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Katherine Poehling, MD, MPH
Chair, ACIP TBE Vaccine Work Group
January 12, 2022

Background

- Food and Drug Administration approved a TBE vaccine (manufactured by Pfizer as TICOVAC) in August 2021
- No TBE vaccine previously licensed in the United States
- No existing ACIP TBE vaccine recommendations
- TBE Vaccine Work Group formed in September 2020 to review use of TBE vaccine in US persons traveling abroad and laboratory workers

TBE Vaccine Work Group members and participants

ACIP

Katherine Poehling (Chair)

Wilbur Chen

CDC Lead

Susan Hills, DVBD

Ex Officio

Rodolfo (Rudy) Alarcon, NIH

Ihid Carneiro Leao, FDA

ACIP liaisons

David Shlim, ISTM

Mark Sawyer, AAP

Technical advisors

Alan Barrett, Univ Texas Galveston

Lin Chen, Mount Auburn Hosp

Tony Marfin, PATH

Bruce McClenathan, DOD

Kayvon Modjarrad, DOD

Technical advisors (cont'd)

Steven Schofield, CATMAT

Bryan Schumacher, DOD

Mary Wilson, Univ Calif SFO

CDC participants

Grace Appiah, DGMQ

Doug Campos-Outcalt, Consultant

Susan Chu, GID

Caitlin Cossaboom, DHCPP

CDC participants (cont'd)

Stacey Martin, DVBD

Michael McNeil, DHQP

Rebecca Morgan, Consultant

Erin Staples, DVBD

Steve Waterman, DVBD

ACIP Secretariat

Jessica MacNeil, NCIRD

Melinda Wharton, NCIRD

Terms of Reference for TBE Vaccine Work Group

- To review information on TBE, including its epidemiology, clinical presentation, diagnosis, treatment, and outcome
- To review data on infection risk and burden for travelers and laboratory workers
- To review data on vaccine safety, immunogenicity, and effectiveness
- To provide evidence-based recommendation options for ACIP
- To identify areas in need of further research for informing potential future vaccine recommendations
- To publish ACIP recommendations in the Morbidity and Mortality Weekly Report (MMWR)

Overview of previous Work Group presentations to ACIP

- October 2020
 - Background on TBE disease and vaccines
 - Summary information on Pfizer's TBE vaccine
- February 2021
 - TBE epidemiology in TBE endemic areas
 - TBE among US civilian travelers and laboratory workers
 - TBE among US military personnel
- September 2021
 - Immunogenicity and safety of Pfizer's TBE vaccine

Overview of today's session

- Follow up of ACIP member questions
 - Immunogenicity of 1 or 2 doses of TBE vaccine
- Evidence to Recommendations for TBE vaccine
 - Persons who travel abroad
 - Laboratory workers
- Next steps

Work Group timeline (planned), Jan–Mar 2022

